Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Earnings Haven't Escaped The Attention Of Investors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) price-to-sales (or "P/S") ratio of 37.8x may look like a poor investment opportunity when you consider close to half the companies in the Biotechs industry in China have P/S ratios below 7.4x. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly elevated P/S.

See our latest analysis for Suzhou Zelgen BiopharmaceuticalsLtd

What Does Suzhou Zelgen BiopharmaceuticalsLtd's P/S Mean For Shareholders?

With revenue growth that's inferior to most other companies of late, Suzhou Zelgen BiopharmaceuticalsLtd has been relatively sluggish. One possibility is that the P/S ratio is high because investors think this lacklustre revenue performance will improve markedly. However, if this isn't the case, investors might get caught out paying too much for the stock.

If you'd like to see what analysts are forecasting going forward, you should check out our free report on Suzhou Zelgen BiopharmaceuticalsLtd.

How Is Suzhou Zelgen BiopharmaceuticalsLtd's Revenue Growth Trending?

In order to justify its P/S ratio, Suzhou Zelgen BiopharmaceuticalsLtd would need to produce outstanding growth that's well in excess of the industry.

Taking a look back first, we see that the company grew revenue by an impressive 26% last year. The latest three year period has also seen an incredible overall rise in revenue, aided by its incredible short-term performance. So we can start by confirming that the company has done a tremendous job of growing revenue over that time.

Shifting to the future, estimates from the four analysts covering the company suggest revenue should grow by 114% over the next year. With the industry only predicted to deliver 56%, the company is positioned for a stronger revenue result.

With this information, we can see why Suzhou Zelgen BiopharmaceuticalsLtd is trading at such a high P/S compared to the industry. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.

The Final Word

Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

Our look into Suzhou Zelgen BiopharmaceuticalsLtd shows that its P/S ratio remains high on the merit of its strong future revenues. It appears that shareholders are confident in the company's future revenues, which is propping up the P/S. Unless these conditions change, they will continue to provide strong support to the share price.

A lot of potential risks can sit within a company's balance sheet. Take a look at our free balance sheet analysis for Suzhou Zelgen BiopharmaceuticalsLtd with six simple checks on some of these key factors.

If these risks are making you reconsider your opinion on Suzhou Zelgen BiopharmaceuticalsLtd, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.